Bio-Rad Laboratories has a Cash Ratio of 3.26. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Bio-Rad Laboratories's Cash Ratio or its related term are showing as below:
BIO'
s Cash Ratio Range Over the Past 10 Years
Min: 1.11 Med: 1.86 Max: 3.53
Current: 3.26
During the past 13 years, Bio-Rad Laboratories's highest Cash Ratio was 3.53. The lowest was 1.11. And the median was 1.86.
BIO's Cash Ratio is ranked better than 77.33% of 825
companies
in the Medical Devices & Instruments industry
Industry Median: 1.1
vs BIO: 3.26
Bio-Rad Laboratories Cash Ratio Historical Data
The historical data trend for Bio-Rad Laboratories's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Bio-Rad Laboratories's Cash Ratio
For the Medical Devices subindustry, Bio-Rad Laboratories's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Rad Laboratories's Cash Ratio Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bio-Rad Laboratories's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Bio-Rad Laboratories's Cash Ratio falls into.
Bio-Rad Laboratories Cash Ratio Calculation
The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.
Bio-Rad Laboratories's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Rad Laboratories (NYSE:BIO) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Bio-Rad Laboratories Cash Ratio Related Terms
Thank you for viewing the detailed overview of Bio-Rad Laboratories's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BIO has been successfully added to your 